Both oral and topical PDE4 inhibitors represent valuable additions to the therapeutic armamentarium for various dermatoses, including approved indications such as psoriasis, atopic dermatitis, and seborrheic dermatitis. Here, PDE4A is linked to seborrheic dermatitis.